CEACAM5 and neoplasm: A nanovaccine that comprises certain tumor antigens like carcinoembryonic antigen (CEA) or mucin 1 (MUC1) that demonstrates a response resistance to sickness and tumor progression has demonstrated promising outcomes in clinical models.